Thalidomide in relapsed or refractory multiple myeloma: How much and for how long?

被引：3
|
作者：
Abdalla, SH
Mahmoud, S
机构：
[1] Imperial Coll Fac Med, London W2 1PG, England
[2] St Marys NHS Trust, London W2 1NY, England
来源：
LEUKEMIA & LYMPHOMA | 2003年 / 44卷 / 06期
关键词：
thalidomide; myeloma; dose; duration;
D O I：
10.1080/1042819031000068016
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The optimum dose and duration of treatment with thalidomide for relapsed or refractory multiple myeloma are not known. Long term responses were seen in 5 patients given low doses of thalidomide (100-200 mg) with or without pulsed dexamethasone, for between 48 and 108 weeks. The responses were sustained for between 23 and 67 weeks after stopping treatment. We recommend that the lowest effective dose (LED) and optimum duration of therapy with thalidomide should be determined within the framework of a well conducted clinical trial in order to answer these important questions.
引用
收藏
页码：989 / 991
页数：3
相关论文
共 50 条
  • [21] How I treat relapsed multiple myeloma
    Kastritis, Efstathios
    Terpos, Evangelos
    Dimopoulos, Meletios A.
    BLOOD, 2022, 139 (19) : 2904 - 2917
  • [22] Thalidomide in the treatment of relapsed multiple myeloma
    Rajkumar, SV
    Fonseca, R
    Dispenzieri, A
    Lacy, MQ
    Lust, JA
    Witzig, TE
    Kyle, RA
    Gertz, MA
    Greipp, PR
    MAYO CLINIC PROCEEDINGS, 2000, 75 (09) : 897 - 901
  • [23] Low-dose thalidomide regimens in therapy of relapsed or refractory multiple myeloma
    Zemanova, M.
    Scudla, V.
    Adam, Z.
    Gregora, E.
    Pour, L.
    Minarik, J.
    Pavlicek, P.
    Pika, T.
    Bacovsky, J.
    NEOPLASMA, 2008, 55 (04) : 345 - 349
  • [24] Thalidomide treatment for relapsed/refractory multiple myeloma: A retrospective multicenter study.
    Bibas, M
    Andriani, A
    Ferrari, A
    Montanaro, M
    Niscola, G
    Recine, U
    Chierichini, A
    BLOOD, 2001, 98 (11) : 307B - 307B
  • [25] LOW-DOSE THALIDOMIDE THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
    Kohei, K. O.
    Ando, S.
    Hasino, S.
    Huse, H.
    Morita, R.
    Takahata, M.
    Onozawa, M.
    Kahata, K.
    Kondo, T.
    Ota, S.
    Kawamura, T.
    Kurosawa, M.
    Aikawa, K.
    Ogawa, T.
    Suzuki, S.
    Takahashi, S.
    Izumiyama, K.
    Iwasaki, H.
    Maemori, M.
    Sakai, H.
    Asaka, M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 619 - 620
  • [26] Low-dosed thalidomide regimens in therapy of relapsed or refractory multiple myeloma
    Zemanova, M.
    Scudla, V.
    Pour, L.
    Gregora, E.
    Pavlicek, P.
    Minarik, J.
    Pika, T.
    Bacovsky, J.
    Adam, Z.
    Hajek, R.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 (06): : 174 - 174
  • [27] Salvage therapy with thalidomide for patients with advanced relapsed/refractory multiple myeloma.
    Tosi, P
    Ronconi, S
    Zamagni, E
    Cellini, C
    Tura, S
    Cavo, M
    BLOOD, 2000, 96 (11) : 296B - 296B
  • [28] Vorinostat, Bortezomib, Cyclophosphomide, Thalidomide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients
    Gleason, Charise
    Kaufman, Jonathan L.
    Nooka, Ajay K.
    Valla, Kelly
    Heffner, Leonard T.
    Bisht, Aditya Singh
    Manubolu, Sanjay
    Watson, Melanie
    Boise, Lawrence H.
    Lonial, Sagar
    BLOOD, 2014, 124 (21)
  • [29] Very low doses of thalidomide as single agent in relapsed/refractory multiple myeloma
    Guglielmelli, Tommasina
    Capella, Sara
    Saglio, Giuseppe
    ACTA HAEMATOLOGICA, 2006, 116 (01) : 70 - 71
  • [30] Combination of bortezomib, thalidomide, and dexamethasone in the treatment of relapsed, refractory IgD multiple myeloma
    Schmielau, J
    Teschendorf, C
    König, M
    Schmiegel, W
    Graeven, U
    LEUKEMIA & LYMPHOMA, 2005, 46 (04) : 567 - 569
12345